skip to content
Primary navigation


Drug - Ilaris® (canakinumab) [Novartis Pharmaceuticals]

September 2019

Therapeutic area - Auto-inflammatory diseases

Approval criteria

  • Patient does not have an active infection or a history of recurring infections AND
  • Patient has negative tuberculin test or, if positive, therapy with isoniazid was initiated at least 1 month prior to request AND
  • Patient is not taking tumor necrosis factor (TNF) inhibitors concomitantly AND
  • Patient has one of the following diagnosis:
    • Cryopyrin-Associated Periodic Syndromes (CAPS) including Familial Cold Autoinflammatory Syndrome (FCAS), Muckle-Wells Syndrome (MWS) AND
      • Patient is ≥ 4 years old OR
    • Tumor Necrosis Factor Receptor Associated Period Syndrome (TRAPS) OR
    • Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) OR
    • Familial Mediterranean Fever (FMF) OR
    • Active Systemic Juvenile Idiopathic Arthritis (SJIA) AND
      • Patient is ≥ 2 years old

Quantity limit

Patient’s most current body weight must be provided at time of request.

Quantity limits depend on patient’s diagnosis.

  • Patients with CAPS and has: 
    • Body weight 15 kg to 40 kg: 3 mg/kg every 8 weeks
    • Body weight greater than 40 kg: 150 mg every 8 weeks
  • Patients with TRAPS, HIDS/MKD, FMF and has: 
    • Body weight 40 kg or less: 4mg/kg every 4 weeks
    • Body weight greater than 40 kg: 300 mg every 4 weeks
  • Patients with SJIA and has:
    • Body weight 7.5 kg or more: 4 mg/kg (max 300 mg) every 4 weeks


MHCP Provider Call Center 651-431-2700 or 800-366-5411

back to top